BIOGEN INC (BIIB) Stock Fundamental Analysis
USA - NASDAQ:BIIB - US09062X1037 - Common Stock
168.18 USD
+0.25 (+0.15%)
168.18 USD
0 (0%)
We assign a fundamental rating of 6 out of 10 to BIIB. BIIB was compared to 533 industry peers in the Biotechnology industry. Both the health and profitability get an excellent rating, making BIIB a very profitable company, without any liquidiy or solvency issues. BIIB is cheap, but on the other hand it scores bad on growth. With these ratings, BIIB could be worth investigating further for value investing!.
1. Profitability
1.1 Basic Checks
BIIB had positive earnings in the past year.
BIIB had a positive operating cash flow in the past year.
Each year in the past 5 years BIIB has been profitable.
Each year in the past 5 years BIIB had a positive operating cash flow.
1.2 Ratios
BIIB's Return On Assets of 5.51% is amongst the best of the industry. BIIB outperforms 92.12% of its industry peers.
Looking at the Return On Equity, with a value of 8.84%, BIIB belongs to the top of the industry, outperforming 92.68% of the companies in the same industry.
BIIB has a better Return On Invested Capital (9.70%) than 94.56% of its industry peers.
BIIB had an Average Return On Invested Capital over the past 3 years of 10.57%. This is significantly below the industry average of 19.19%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.51% | ||
| ROE | 8.84% | ||
| ROIC | 9.7% |
ROA(3y)7.52%
ROA(5y)9.06%
ROE(3y)13.45%
ROE(5y)18.4%
ROIC(3y)10.57%
ROIC(5y)13.65%
1.3 Margins
The Profit Margin of BIIB (15.99%) is better than 93.43% of its industry peers.
BIIB's Profit Margin has declined in the last couple of years.
With an excellent Operating Margin value of 28.50%, BIIB belongs to the best of the industry, outperforming 96.44% of the companies in the same industry.
In the last couple of years the Operating Margin of BIIB has declined.
BIIB has a Gross Margin of 75.24%. This is amongst the best in the industry. BIIB outperforms 83.68% of its industry peers.
BIIB's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 28.5% | ||
| PM (TTM) | 15.99% | ||
| GM | 75.24% |
OM growth 3Y-4.87%
OM growth 5Y-12.22%
PM growth 3Y5.98%
PM growth 5Y-16.26%
GM growth 3Y-1.51%
GM growth 5Y-2.23%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), BIIB is creating some value.
Compared to 1 year ago, BIIB has more shares outstanding
BIIB has less shares outstanding than it did 5 years ago.
Compared to 1 year ago, BIIB has an improved debt to assets ratio.
2.2 Solvency
BIIB has an Altman-Z score of 3.23. This indicates that BIIB is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of BIIB (3.23) is better than 72.05% of its industry peers.
BIIB has a debt to FCF ratio of 2.78. This is a good value and a sign of high solvency as BIIB would need 2.78 years to pay back of all of its debts.
BIIB has a better Debt to FCF ratio (2.78) than 93.06% of its industry peers.
BIIB has a Debt/Equity ratio of 0.35. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of BIIB (0.35) is worse than 70.17% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.35 | ||
| Debt/FCF | 2.78 | ||
| Altman-Z | 3.23 |
ROIC/WACC1.17
WACC8.29%
2.3 Liquidity
BIIB has a Current Ratio of 2.72. This indicates that BIIB is financially healthy and has no problem in meeting its short term obligations.
BIIB's Current ratio of 2.72 is on the low side compared to the rest of the industry. BIIB is outperformed by 66.98% of its industry peers.
BIIB has a Quick Ratio of 2.04. This indicates that BIIB is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of BIIB (2.04) is worse than 73.17% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.72 | ||
| Quick Ratio | 2.04 |
3. Growth
3.1 Past
BIIB shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 2.51%.
The earnings per share for BIIB have been decreasing by -13.31% on average. This is quite bad
The Revenue has been growing slightly by 4.77% in the past year.
Measured over the past years, BIIB shows a decrease in Revenue. The Revenue has been decreasing by -7.62% on average per year.
EPS 1Y (TTM)2.51%
EPS 3Y-4.95%
EPS 5Y-13.31%
EPS Q2Q%17.89%
Revenue 1Y (TTM)4.77%
Revenue growth 3Y-4.13%
Revenue growth 5Y-7.62%
Sales Q2Q%2.79%
3.2 Future
BIIB is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 0.52% yearly.
BIIB is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -0.65% yearly.
EPS Next Y-5.79%
EPS Next 2Y-2.63%
EPS Next 3Y-0.37%
EPS Next 5Y0.52%
Revenue Next Year1.35%
Revenue Next 2Y-1.88%
Revenue Next 3Y-1.34%
Revenue Next 5Y-0.65%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 10.05, the valuation of BIIB can be described as very reasonable.
BIIB's Price/Earnings ratio is rather cheap when compared to the industry. BIIB is cheaper than 97.56% of the companies in the same industry.
BIIB is valuated cheaply when we compare the Price/Earnings ratio to 25.47, which is the current average of the S&P500 Index.
A Price/Forward Earnings ratio of 10.77 indicates a reasonable valuation of BIIB.
Based on the Price/Forward Earnings ratio, BIIB is valued cheaper than 97.56% of the companies in the same industry.
BIIB's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 35.42.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.05 | ||
| Fwd PE | 10.77 |
4.2 Price Multiples
BIIB's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. BIIB is cheaper than 97.94% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, BIIB is valued cheaper than 98.31% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 10.9 | ||
| EV/EBITDA | 7.39 |
4.3 Compensation for Growth
BIIB has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-2.63%
EPS Next 3Y-0.37%
5. Dividend
5.1 Amount
BIIB does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
168.18
+0.25 (+0.15%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners92.49%
Inst Owner Change1.97%
Ins Owners0.14%
Ins Owner Change5.21%
Market Cap24.66B
Revenue(TTM)10.07B
Net Income(TTM)1.61B
Analysts73.81
Price Target175.03 (4.07%)
Short Float %3.86%
Short Ratio3.21
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)30.2%
Min EPS beat(2)21.48%
Max EPS beat(2)38.92%
EPS beat(4)4
Avg EPS beat(4)19.59%
Min EPS beat(4)0.67%
Max EPS beat(4)38.92%
EPS beat(8)8
Avg EPS beat(8)14.8%
EPS beat(12)12
Avg EPS beat(12)12.19%
EPS beat(16)14
Avg EPS beat(16)11.4%
Revenue beat(2)2
Avg Revenue beat(2)8.93%
Min Revenue beat(2)6.23%
Max Revenue beat(2)11.62%
Revenue beat(4)4
Avg Revenue beat(4)6.16%
Min Revenue beat(4)0.11%
Max Revenue beat(4)11.62%
Revenue beat(8)5
Avg Revenue beat(8)2.19%
Revenue beat(12)9
Avg Revenue beat(12)2.33%
Revenue beat(16)11
Avg Revenue beat(16)2%
PT rev (1m)1.06%
PT rev (3m)1.25%
EPS NQ rev (1m)-54.08%
EPS NQ rev (3m)-54.76%
EPS NY rev (1m)-4.15%
EPS NY rev (3m)1.63%
Revenue NQ rev (1m)-2.3%
Revenue NQ rev (3m)-2.13%
Revenue NY rev (1m)0.95%
Revenue NY rev (3m)5.45%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.05 | ||
| Fwd PE | 10.77 | ||
| P/S | 2.45 | ||
| P/FCF | 10.9 | ||
| P/OCF | 10.05 | ||
| P/B | 1.35 | ||
| P/tB | 10.34 | ||
| EV/EBITDA | 7.39 |
EPS(TTM)16.74
EY9.95%
EPS(NY)15.61
Fwd EY9.28%
FCF(TTM)15.44
FCFY9.18%
OCF(TTM)16.74
OCFY9.95%
SpS68.66
BVpS124.19
TBVpS16.27
PEG (NY)N/A
PEG (5Y)N/A
Graham Number216.28
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.51% | ||
| ROE | 8.84% | ||
| ROCE | 11.07% | ||
| ROIC | 9.7% | ||
| ROICexc | 11.44% | ||
| ROICexgc | 40.96% | ||
| OM | 28.5% | ||
| PM (TTM) | 15.99% | ||
| GM | 75.24% | ||
| FCFM | 22.48% |
ROA(3y)7.52%
ROA(5y)9.06%
ROE(3y)13.45%
ROE(5y)18.4%
ROIC(3y)10.57%
ROIC(5y)13.65%
ROICexc(3y)12.43%
ROICexc(5y)16.11%
ROICexgc(3y)38.35%
ROICexgc(5y)40.12%
ROCE(3y)12.07%
ROCE(5y)15.58%
ROICexgc growth 3Y14.16%
ROICexgc growth 5Y-5.35%
ROICexc growth 3Y-15.93%
ROICexc growth 5Y-20.8%
OM growth 3Y-4.87%
OM growth 5Y-12.22%
PM growth 3Y5.98%
PM growth 5Y-16.26%
GM growth 3Y-1.51%
GM growth 5Y-2.23%
F-Score5
Asset Turnover0.34
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.35 | ||
| Debt/FCF | 2.78 | ||
| Debt/EBITDA | 1.73 | ||
| Cap/Depr | 25% | ||
| Cap/Sales | 1.9% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 67.56% | ||
| Profit Quality | 140.56% | ||
| Current Ratio | 2.72 | ||
| Quick Ratio | 2.04 | ||
| Altman-Z | 3.23 |
F-Score5
WACC8.29%
ROIC/WACC1.17
Cap/Depr(3y)54.41%
Cap/Depr(5y)68.88%
Cap/Sales(3y)3.09%
Cap/Sales(5y)3.21%
Profit Quality(3y)99.36%
Profit Quality(5y)121%
High Growth Momentum
Growth
EPS 1Y (TTM)2.51%
EPS 3Y-4.95%
EPS 5Y-13.31%
EPS Q2Q%17.89%
EPS Next Y-5.79%
EPS Next 2Y-2.63%
EPS Next 3Y-0.37%
EPS Next 5Y0.52%
Revenue 1Y (TTM)4.77%
Revenue growth 3Y-4.13%
Revenue growth 5Y-7.62%
Sales Q2Q%2.79%
Revenue Next Year1.35%
Revenue Next 2Y-1.88%
Revenue Next 3Y-1.34%
Revenue Next 5Y-0.65%
EBIT growth 1Y15.15%
EBIT growth 3Y-8.8%
EBIT growth 5Y-18.9%
EBIT Next Year7.73%
EBIT Next 3Y2.84%
EBIT Next 5Y1.64%
FCF growth 1Y120.54%
FCF growth 3Y-9.06%
FCF growth 5Y-17.06%
OCF growth 1Y80.48%
OCF growth 3Y-7.55%
OCF growth 5Y-16.48%
BIOGEN INC / BIIB FAQ
Can you provide the ChartMill fundamental rating for BIOGEN INC?
ChartMill assigns a fundamental rating of 6 / 10 to BIIB.
What is the valuation status for BIIB stock?
ChartMill assigns a valuation rating of 7 / 10 to BIOGEN INC (BIIB). This can be considered as Undervalued.
How profitable is BIOGEN INC (BIIB) stock?
BIOGEN INC (BIIB) has a profitability rating of 7 / 10.
Can you provide the expected EPS growth for BIIB stock?
The Earnings per Share (EPS) of BIOGEN INC (BIIB) is expected to decline by -5.79% in the next year.